Suzhou Terry Pharmaceutical

Suzhou Terry Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule drugs. The company primarily targets metabolic diseases, with a significant emphasis on treatments for type 2 diabetes and hyperuricemia. Its pipeline includes novel SGLT2 inhibitors and DPP-4 inhibitors designed to provide improved efficacy and safety profiles for patients. Suzhou Terry Pharmaceutical leverages its internal research capabilities to advance candidates from early discovery through clinical validation within the Chinese regulatory framework.